Introduction
A variety of vectors for gene transfer into hepatocytes in vitro and in vivo has been described. 1 Despite tremendous efforts in the development of potent gene transfer vectors, various problems still exist in the use of basically all currently existing gene delivery systems. Investigation of the causality of failures is the basis for the improvement of gene transfer vectors.
We have previously developed a baculovirus vector for efficient gene transfer into hepatocytes in vitro. 2 Baculovirus-mediated gene transfer into mammalian cells has been confirmed by others. 3 However, a successful gene delivery in vivo using baculovirus vectors has not yet been reported. In fact, we could demonstrate the feasibility of baculovirus-mediated gene transfer into ex vivo perfused human liver tissue, but could also demonstrate in the same study that gene transfer by baculovirus vectors is strongly reduced in the presence of native serum. 4 The latter effect is most likely due to inactivation of baculovirus by the complement (C) system.
The C system represents a first-line host defense of the innate immune system designed to eliminate foreign elements. 5, 6 It serves as a powerful recognition and effector system of humoral immunity ensuring direct lysis of C sensitive intruders and/or their opsonization for rapid clearance by the reticuloendothelial system. Additionally, along the C cascade, anaphylotoxins are released to recruit immune defensive cells and proteins from the per- iphery to mediate an inflammatory response in the area of C activation.
Therefore, the C system has to be considered with regard to the biocompatibility of gene transfer vectors that had never been subjected to C attack during evolution. Triggering of the C cascade is a major cause for the inactivation of a variety of currently used gene delivery vectors and contributes to inefficient gene transfer rates after in vivo application. C activation has been shown for liposomes, [7] [8] [9] for various synthetic DNA complexes 10 and for murine retrovirus vectors in primate serum. [11] [12] [13] In this study, the interaction of baculovirus with the human C system was investigated in detail with regard to the use of baculovirus-derived vectors in vivo. We demonstrate that baculovirus vectors activate the classical pathway of the C system and assembly of very late C components is required for inactivation of the vector. Since survival of baculovirus vectors in the presence of C is a prerequisite for successful gene transfer in vivo, we attempted to block C in human serum. Inhibition of C component 5 with a functionally blocking monoclonal antibody increased the survival of baculovirus vectors in human serum in a dose-dependent manner. Furthermore, inactivation of baculovirus vectors in whole blood can be prevented by treatment with the C inhibitor cobra venom factor. Our findings reveal immunological interactions of baculovirus vectors with the C system and provide possible solutions for successful baculovirus-mediated gene transfer in vivo.
Results
Baculovirus triggered activation of the complement cascade Recent studies have shown that baculovirus-mediated gene transfer into hepatocytes is strongly reduced in the presence of untreated human serum in contrast to heatinactivated serum or complement (C)-deficient guinea pig sera. 4 These data indicated that the C system has an impact on baculovirus survival in vivo.
In this study, we investigated in more detail the fate of baculovirus vectors in the presence of C. Baculovirus survival was determined in an inhibition assay by gene transfer into Huh7 cells with a luciferase expressing baculovirus vector (AcNPV-CMVL 2 ) preincubated with either the investigated serum or the corresponding heat-treated serum. Survival was recorded as the percentage of luciferase activity obtained with the indicated pretreatment compared with treatment with the respective heatinactivated serum. Preincubation of baculovirus with pooled human serum as the source of C resulted in baculovirus inactivation in a dose-dependent manner, ranging from nearly 100% vector survival in 1% serum to only 1% vector survival in 90% serum ( Figure 1 ).
A general overview of possible interactions of baculoviruses with the C system is shown in Figure 2 . The activation of the C cascade can be triggered by the alternative, 5, 6 or the lectin 14 or the classical pathway. 5, 6 The alternative pathway is linked to the other pathways through C3b thereby providing an amplification (positive feedback) loop.
In order to investigate the influence of C activation on baculovirus survival, we exposed baculovirus vectors to 40% native human serum or to sera depleted in early C components with or without EGTA-Mg treatment (Figure 3a) . Baculovirus vector survival was significantly increased by EGTA-Mg-treated human serum, indicating These data suggest that baculovirus triggers the activation of the classical pathway of the C cascade in human serum. Significant levels of pre-existing antibodies in human serum (IgG or IgM) against baculovirus proteins that could be responsible for C activation were not detected by ELISA or Western blotting (data not shown).
Baculovirus vector survival in the presence of human sera depleted in late complement components In order to determine if the reduction of baculovirusmediated gene transfer is dependent on assembly of the membrane attack complex (MAC), we exposed the vector to human sera depleted in late C components (C3-C9). No significant reduction in baculovirus vector survival could be observed in the presence of sera depleted in C components C3-7, whereas C8 and C9 depletion of the sera resulted in a marked inactivation of the vector (Figure 3b ). These experiments confirm, on the one hand, that baculovirus vectors are inactivated by the C system and, on the other hand, suggest that assembly of C5-7 may already be sufficient to cause significant virus inactivation even in the absence of C8 and C9. Survival of baculovirus in human serum depleted of various individual components of the C may provide the possibility of protecting baculovirus from C inactivation by inhibition at numerous steps of the C cascade.
Protection of baculovirus vectors in human serum by anti-C5 monoclonal antibody (mAb)
Since baculovirus-mediated gene transfer is not inhibited in the presence of serum depleted in C component 5 (C5), we aimed at virus protection by the treatment of human serum with a functional blocking anti-C5 mAb. This treatment increased baculovirus vector survival in human serum significantly in a dose-dependent manner ( Figure 4) . No protection of baculovirus in human serum was observed by treatment with a control antibody. Antibody treatment did not interfere with the inhibition assay on Huh7 cells per se (not shown).
Baculovirus survival in human plasma and blood All previous experiments to evaluate the interaction of baculovirus with the C system were carried out using serum as a source of complement. We extented this study by investigating the fate of baculovirus in human plasma and blood. In order to inhibit coagulation of plasma and blood, we used recombinant hirudin. The coagulationblockers EDTA and citrate that are normally used inhibit the C cascade and heparin blocks baculovirus gene transfer into Huh7 cells per se (data not shown). The use of either recombinant hirudin or Refludan did not interfere with the assay and led to equal results. Preincubation of the baculovirus vector with untreated hirudinized human
Figure 2 Baculovirus and the complement (C) system. Alternative, lectin and classical pathways of C activation are illustrated with regard to their potential influence on baculovirus inactivation in human serum. Unique components within each of the three pathways allow for systematic analysis of interactions of baculovirus vectors with C. All pathways converge on component C3 and end in formation of the membrane attack complex (MAC). The function of C3-C5 convertases (shadowed) are represented by broken lines. The interference of the C3b-like protein, cobra venom factor (CVF), with C is indicated.
plasma or blood resulted in less than 1% survival of baculovirus vector compared with heat-inactivated plasma. In contrast, cobra venom factor (CVF) treatment of both plasma and blood led to almost complete protection of the vector ( Figure 5 ). The striking similarity of CVF to C3b 15 enables this factor to participate in the formation of an abnormal C3/C5 convertase, which depletes the C cascade in C3 and later components. 16 
Discussion
Baculovirus vectors provide efficient means for gene transfer into hepatocytes [2] [3] [4] and human liver tissue. 4 Besides these features, potential advantages of baculovirus vectors are the nearly umlimited capacity for the insertion of foreign DNA, 17 a supposed restriction of viral promoters to the arthropod host and the ease of generating high vector titers. 18 This study addressed a problem that so far has posed a major hurdle for the success of baculovirus vectors in vivo, the complement (C) system. The C cascade is usually activated to protect the host from foreign elements. Since baculovirus derives from insect cells, which represent a phylogenetical low host, interactions of this virus with C of higher evolved species could have been expected. The C activating properties of various gene transfer vectors such as liposomes, [7] [8] [9] other synthetic DNA complexes 10 based on polylysins, dendrimers or polyethylenimine, and murine retroviruses was already demonstrated. The mechanism and extent of C activation by liposomes and synthetic DNA complexes depends mainly on the formulation, charge and size. 9, 19, 20 Cationic liposomes, for example, activate the alternative pathway, whereas anionic liposomes trigger the classical pathway of the C cascade.
21 C-mediated virus neutralization can occur by aggregation, by envelopment with protein, or by lysis. Murine retroviruses are effectively lysed by primate C. 11 Lysis is triggered by the classical C pathway, involving direct binding of C1q and C1s to the envelope protein p15E 12 and/or anti-Gal(␣1-3)Gal antibodies. 13, 22 In analogy to murine retrovirus vectors, 23 we found baculovirus survival in C1q-depleted (d) human serum indicating baculovirus-mediated activation of the C cascade through the classical C pathway. This result excluded the possibility of C activation through the lectin 14 pathway, since this pathway is dependent on mannan-binding protein-associated serine proteases 24, 25 and does not require C1q. The alternative C pathway is primarily not activated by baculovirus vectors, since inactivation of baculovirus in factor B-depleted serum could be prevented by additional blocking of the classical pathway through EGTA-Mg treatment. The alternative C pathway serves, however, the amplification of C3b generated through the classical pathway (Figure 2) . Activation of the classical C pathway by baculovirus was additionally supported by a marked survival of the virus in EGTA-Mg-treated human serum and in C2d serum. Partial inactivation in C2d serum most likely reflects residual C activity due to incomplete C2 depletion. In support of this explanation, the latter effect could be abolished by additional serum treatment with EGTA-Mg. The presence of pre-existing IgG or IgM antibodies in human serum against baculovirus proteins could not be proven, suggesting antibody-independent activation of the classical C pathway by baculovirus. However, it cannot be ruled out completely that traces of natural, heterophilic antibodies in human serum recognize molecules on the baculovirus surface and sub-
Figure 3 Baculovirus survival in complement (C)-depleted human sera. Baculovirus was subjected to 40% human serum or 40% human serum depleted (d) in early C components with or without EGTA-Mg treatment (a) and human serum depleted in C3 or terminal (C5d-C9d) C components (b). Bars denote the percentage of vector survival in the indicated sera referred to the corresponding heat-treated sera. Data represent mean values of two experiments with duplicate samples each ± standard error.
sequently activate C1 by analogy with C activation by murine retroviruses triggered through anti-Gal(␣1-3)Gal antibodies. 13, 22 Analysis of the fate of baculovirus in human sera depleted in C3 and individual components of the membrane attack complex (MAC, C5-C9) revealed survival of the virus until addition of C7. C7 confers lipophilicity and membrane attachment capability 26, 27 to the previously formed complex and thus might cause the marked inactivation of baculovirus in C8d (respectively C9d) human serum through envelopment or derangement of the baculoviral surface. The survival rate of baculovirus in C8d and C9d human serum is still significantly higher than in complete human serum, which might indicate that MAC formation is required for complete vector inactivation and that this inactivation occurs through virolysis. However, both, involvement of virolysis 11, 23 and a step before C7 deposition 28 in complementmediated inhibition of viral infectivity are matters of controversial discussion.
The survival of baculovirus until the formation of very late C components does not, however, exclude the possi- 
Figure 5 Baculovirus survival in human plasma and blood. Baculovirus vectors were subjected to 90% human plasma or blood with or without cobra venom factor (CVF) treatment. Coagulation of plasma and blood was inhibited by hirudin. Bars indicate the percentage of baculovirus vector survival following respective treatment referred to heat-treated plasma (⌬ H-plasma). Data represent mean values of two experiments with duplicate samples each ± standard error.
bility of baculovirus vector removal by the reticuloendothelial system through opsonization in vivo.
A major goal of this study was to evaluate the interaction of baculovirus vectors with the C system in order to establish strategies to protect the vector from C inactivation. By treatment of human serum with increasing amounts of a functional blocking mAb against C5, we observed baculovirus vector survival in a dosedependent manner. The usefulness of anti-C5 mAb 29 and recombinant anti-C5 antibody fragments 30 to inhibit C activity has already been demonstrated in vitro and in vivo. These results support the feasibility of baculovirusmediated gene transfer in vivo by simultaneous application of C blocking antibodies. In addition, C5 deficient mice 31 could serve for first in vivo approaches using baculovirus vectors.
We also addressed in this study the fate of baculovirus vectors in plasma and whole human blood as a source of C. Coagulation of plasma and blood was prevented by hirudin, because heparin blocked baculovirus infection of Huh7 cells per se. Provided the observed effect of heparin is due to its polyanionic structure, one may speculate that polyanion clusters on the surface of baculovirus are involved in both its uptake by hepatocytes and C activation. The latter assumption is supported by the ability of C1q to bind directly to complexes of polyanions 32 including heparin. 33 The inactivation of baculovirus in untreated human plasma and blood was expected from the results of the experiments using serum as a source of C. However, baculovirus survival in plasma and blood could be achieved by treatment with cobra venom factor. CVF has been safely administered in a variety of experiments to block the C cascade in animals. [34] [35] [36] [37] Thus, it may provide an additional method of protecting baculovirus vectors from C inactivation.
Based on the results of this study, two principal possibilities to protect baculovirus vectors from C inactivation in vivo become apparent. Protection can either be achieved by depletion or exclusion of the C system in animal models before baculovirus application or by modification of the existing baculovirus vectors. Depletion of the C system is feasible by application of antibodies directed against distinct C components or CVF (this study). Furthermore, the use of soluble C receptors 38 (sCR1) for inhibition of the C cascade could support baculovirusmediated gene transfer in vivo. Exclusion of the C system seems to be likely by in situ perfusion methods, which have already been carried out in the course of retrovirusmediated gene transfer into the liver in vivo. [39] [40] [41] Thus, through exploration of the mechanisms precluding infection of liver cells in vivo by baculovirus vectors, we should be able to circumvent these mechanisms, rendering baculovirus a useful tool for human gene therapy. Even if inactivation of the C system in vivo is feasible, the ultimate goal should be generation of C-resistant viruses. Our current strategies are based on screening of baculovirus mutants as well as on the insertion of C regulating molecules, such as decay accelerating factor, 42 into the viral envelope.
Materials and methods
Viruses and cells SF9 insect cells were cultured in spinner flasks (INTEGRA Biosciences, Fernwald, Germany) in Excell 401-medium (Biozol, Eching, Germany) containing 10% fetal calf serum.
Recombinant baculoviruses, AcNPV-CMVL, 2 contain the luciferase reporter gene under control of the cytomegalovirus (CMV) immediate-early promoter. They were propagated by infection of SF9 cells at a density of 2 × 10 6 cells/ml with a multiplicity of infection (MOI) of 0.1 plaque forming units (p.f.u.) per cell. Four days after infection the tissue-culture fluid was harvested and virus was concentrated by sedimentation at 80 000 g for 75 min at 4°C through a 25% (w/v) sucrose cushion (3 ml) using a SW 28 rotor (Beckman Instruments, Munich, Germany). Further purification was obtained by centrifugation at 96 000 g for 3 h at 4°C in a 25-60% (w/v) linear sucrose gradient using a Beckman SW 40 rotor. The white band at 47-49% sucrose, containing the baculovirus, was collected, diluted with phosphate-buffered saline (PBS) and pelleted at 80 000 g for 75 min at 4°C using a Beckman SW 40 rotor. The pellet was resuspended in PBS, stored in small aliquots at −80°C, and titrated on SF9 cells by plaque assay.
The human hepatocellular carcinoma cell line Huh7 43 was cultured as described 4 and incubated with baculovirus containing samples at a constant cell density of 2 x 10 5 cells per well (24-well plates) in all assays.
Baculovirus inhibition assay in human serum
The study included native pooled human serum (hemolytic titer: 37 CH50 U/ml), human sera depleted (d) in components of the complement system: C1qd, C2d, C3d, C5d, C6d, C7d, C8d, C9d ((SIGMA-ALDRICH, Deisenhofen, Germany) and CBd (Quidel, San Diego, CA, USA). Heat treatment of the serum was performed by incubation at 56°C for 30 min. EGTA-Mg-treated serum contained 10 mM EGTA and 7 mM MgCl 2 .
In experiments to inhibit complement-dependent inactivation of baculovirus, native and heat-inactivated human sera were pretreated for 30 min at 37°C with increasing amounts of MAb directed against human C5 (A217; Quidel) or against hepatitis B virus surface antigen (H166 44 ) as control mAb. Purified AcNPV-CMVL, representing a MOI of 100 in the infection assay, was diluted in Gey's balanced salt solution (GBSS) and incubated for 30 min at 37°C with each serum to a serum end concentration of 40% (if not otherwise indicated) in a total of 100 l. After this preincubation, Huh7 cells were incubated at 37°C for 1 h with serum-treated virus and assayed for luciferase activity after 42 h.
Baculovirus inhibition assay in hirudinized human plasma and blood Blood was freshly drawn from healthy volunteers and hirudinized using either 50 U recombinant leech hirudin/ml blood (SIGMA-ALDRICH) or 5 g/ml Lepirudin (Refludan; Behringwerke AG, Marburg, Germany). Hirudin plasma was isolated from hirudin-treated blood by centrifugation at 3000 g for 10 min at 4°C. Heat treatment of plasma was performed by incubation at 56°C for 30 min. Cobra venom factor (CVF) treatment was carried out by incubation with 5 U CVF (Naja naja kaouthia; Quidel) per ml plasma, respectively, blood at 37°C for 1 h.
For the inhibition assay, 2 × 10 7 p.f.u. purified AcNPV-CMVL in 10 l GBSS were added to 90 l each of plasma or blood sample and incubated for 30 min at 37°C with shaking. Then, 900 l Huh7 cell culture medium was added and each sample was centrifuged at 3000 g for 2 min. The supernatants were incubated with Huh7 cells for 1 h. Luciferase activity was measured 42 h later.
Detection of luciferase activity Cells were washed twice with ice-cold PBS and harvested from the culture dish with lysis buffer (100 mM potassium phosphate buffer (pH 7.8), 1% Triton X-100 and 1 mM dithiothreitol). The lysate was cleared from cell debris by centrifugation. Dilution series of the lysate in 50 l were added to 180 l reaction buffer (25 mM potassium phosphate (pH 7.8), 4 mM EGTA, 15 mM MgSO 4 , 1 mM ATP, 1 mM DTT). The reaction was started by injection of 50 l of 100 M luciferin and light emission was measured using a luminometer (Lumat, Berthold, Germany).
